Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France
MRC-Gard
Feasibility Study on Estimating the Prevalence and Management of Stage 4 Chronic Kidney Disease in Adults Via Laboratories and Nephrologists in the Gard, France
1 other identifier
observational
3,375
1 country
4
Brief Summary
The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2019
Longer than P75 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 18, 2016
CompletedFirst Posted
Study publicly available on registry
October 19, 2016
CompletedStudy Start
First participant enrolled
January 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedMarch 10, 2025
March 1, 2025
6.9 years
October 18, 2016
March 7, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (raw number)
from baseline (day 0) to 12 months
The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (%)
from baseline (day 0) to 12 months
Secondary Outcomes (3)
The percentage of patients with CKD stage >= 4 correctly reported by participating nephrologists
from baseline (day 0) to 12 months
For each nephrologist participating in the study, the % of patients with stage >=4 chronic kidney disease who are correctly declared
from baseline (day 0) to 12 months
The % of patients with chronic kidney disease stage > = 4 in the Gard according to laboratory data and who are not seen by a nephrologist
from baseline (day 0) to 12 months
Study Arms (1)
The study population
Persons with stage \>=4 chronic kidney disease.
Eligibility Criteria
Persons with \>= stage 4 chronic kidney disease and residing in the Gard department of France.
You may qualify if:
- chronic kidney disease (stage \>= 4)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
AIDER - Unité de Dialyse d'Alès
Alès, 30100, France
AIDER - Unité de Dialyse de Nîmes, CHU Carémeau
Nîmes, 30029, France
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
Gardialyse
Nîmes, 30900, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Olivier Moranne, MD, PhD
Centre Hospitalier Universitaire de Nîmes
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 18, 2016
First Posted
October 19, 2016
Study Start
January 1, 2019
Primary Completion
December 1, 2025
Study Completion
December 1, 2025
Last Updated
March 10, 2025
Record last verified: 2025-03